Osteosarcoma in Children: Not Only Chemotherapy

被引：33

作者：

Argenziano, Maura ^{[1
]}

Tortora, Chiara ^{[1
]}

Pota, Elvira ^{[1
]}

Di Paola, Alessandra ^{[2
]}

Di Martino, Martina ^{[1
]}

Di Leva, Caterina ^{[1
]}

Di Pinto, Daniela ^{[1
]}

Rossi, Francesca ^{[1
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, I-80138 Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Expt Med, I-80138 Naples, Italy

来源：

PHARMACEUTICALS | 2021年 / 14卷 / 09期

关键词：

osteosarcoma; chemoresistance; therapy; proteasome inhibitors; immunotherapy; iron chelation; lncRNA; TKIs; IRON CHELATOR; IN-VITRO; GLEMBATUMUMAB VEDOTIN; TRANSFERRIN RECEPTOR; OSTEOGENIC-SARCOMA; METASTATIC NICHE; CANCER-TREATMENT; HIGH-GRADE; PROTEASOME; CELLS;

D O I：

10.3390/ph14090923

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Osteosarcoma (OS) is the most severe bone malignant tumor, responsible for altered osteoid deposition and with a high rate of metastasis. It is characterized by heterogeneity, chemoresistance and its interaction with bone microenvironment. The 5-year survival rate is about 67% for patients with localized OS, while it remains at 20% in case of metastases. The standard therapy for OS patients is represented by neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. The most used chemotherapy regimen for children is the combination of high-dose methotrexate, doxorubicin, and cisplatin. Considered that the necessary administration of high-dose chemotherapy is responsible for a lot of acute and chronic side effects, the identification of novel therapeutic strategies to ameliorate OS outcome and the patients' life expectancy is necessary. In this review we provide an overview on new possible innovative therapeutic strategies in OS.

引用

页数：18

共 172 条

[1]

Ahn Ju Hyun, 2015, Ann Pediatr Endocrinol Metab, V20, P150, DOI 10.6065/apem.2015.20.3.150

[2] Bone microenvironment signals in osteosarcoma development [J].

Alfranca, Arantzazu ;

Martinez-Cruzado, Lucia ;

Tornin, Juan ;

Abarrategi, Ander ;

Amaral, Teresa ;

de Alava, Enrique ;

Menendez, Pablo ;

Garcia-Castro, Javier ;

Rodriguez, Rene .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (16) :3097-3113

[3] Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases [J].

Aljubran, A. H. ;

Griffin, A. ;

Pintilie, M. ;

Blackstein, M. .

ANNALS OF ONCOLOGY, 2009, 20 (06) :1136-1141

[4] Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages [J].

Alkhateeb, Ahmed A. ;

Han, Bing ;

Connor, James R. .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (03) :733-744

[5]

Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872

[6] Mifamurtide for the treatment of nonmetastatic osteosarcoma [J].

Ando, Kosei ;

Mori, Kanji ;

Corradini, Nedege ;

Redini, Francoise ;

Heymann, Dominique .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (02) :285-292

[7] Iron homeostasis [J].

Andrews, Nancy C. ;

Schmidt, Paul J. .

ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 :69-85

[8] Effects of Iron Chelation in Osteosarcoma [J].

Argenziano, Maura ;

Di Paola, Alessandra ;

Tortora, Chiara ;

Di Pinto, Daniela ;

Pota, Elvira ;

Di Martino, Martina ;

Perrotta, Silverio ;

Rossi, Francesca ;

Punzo, Francesca .

CURRENT CANCER DRUG TARGETS, 2021, 21 (05) :443-455

[9] Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells [J].

Augello, Giuseppa ;

Modica, Martina ;

Azzolina, Antonina ;

Puleio, Roberto ;

Cassata, Giovanni ;

Emma, Maria Rita ;

Di Sano, Caterina ;

Cusimano, Antonella ;

Montalto, Giuseppe ;

Cervello, Melchiorre .

CELL DEATH & DISEASE, 2018, 9

[10] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [J].

Bachelot, T. ;

Ciruelos, E. ;

Schneeweiss, A. ;

Puglisi, F. ;

Peretz-Yablonski, T. ;

Bondarenko, I. ;

Paluch-Shimon, S. ;

Wardley, A. ;

Merot, J. -L. ;

du Toit, Y. ;

Easton, V. ;

Lindegger, N. ;

Miles, D. ;

Bouzid, Kamel ;

Campone, Mario ;

Coudert, Bruno ;

Nowecki, Zbigniew ;

Errihani, Hassan ;

Dalenc, Florence ;

Ferreira, Ana ;

Mano, Max ;

Ricci, Francesco ;

Kalofonos, Haralabos ;

Andreetta, Claudia ;

Montemurro, Filippo ;

Barrett, Sophie ;

Zhang, Qingyuan ;

Mavroudis, Dimitris ;

Matus, Juan ;

Beato, Carlos ;

Hu, Xichun ;

Gaafar, Rabab ;

Azeem, Hamdy Abdel ;

Perrin, Christophe ;

Ettl, Johannes ;

Lang, Istvan ;

Verma, Sunil ;

Li, Huiping ;

Brain, Etienne ;

Hoffmann, Oliver ;

Cariello, Anna ;

Tondini, Carlo ;

Altwegeiri, Taher ;

Loman, Niklas ;

Lux, Michael ;

Frassoldati, Antonio ;

Aziz, Zeba ;

Salas, Fernando ;

Streb, Joanna ;

Wronski, Andrzej .

ANNALS OF ONCOLOGY, 2019, 30 (05) :766-773

← 1 2 3 4 5 6 7 8 9 10 →